BioTuesdays
StemCells

StemCells and Microbot Medical to merge

StemCells (NASDAQ:STEM) and closely-held Microbot Medical of Israel have entered into a definitive merger agreement, with plans to pursue the development of robotics-based medical devices for the treatment of...

Cellect Biotechnology

Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary...

oramed

Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between...

Spartan Bioscience Logo

Spartan announces first applications for Cube

Closely-held Spartan Bioscience has launched the world’s smallest commercial molecular diagnostic device, the Spartan Cube, and announced its first assay applications. They are Strep A, Apolipoprotein E, a genetic...

oramed

Oramed posts positive oral insulin data

Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically...

Anavex Life Sciences

Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in...

Viking Therapeutics Logo

Viking reports positive POC study in X-ALD

Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD). The results showed that VK0214 rapidly reduced...

Anavex Life Sciences

Anavex presents safety data in AD

Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto. Data presented in a poster highlights the evaluation...

ProMIS Neurosciences

ProMIS in new program to identify ALS targets

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and...

ProMIS Neurosciences

ProMIS announces new AZ program

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the...